0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Editorial |  ONLINE FIRST
Mitchell H. Katz, MD
JAMA Intern Med. Published online March 15, 2016. doi:10.1001/jamainternmed.2016.0664

Editorial | 
Steven R. Cummings, MD; Douglas P. Kiel, MD, MPH; Dennis M. Black, PhD
JAMA Intern Med. 2016;176(2):171-172. doi:10.1001/jamainternmed.2015.7568.

Original Investigation | 
Heike A. Bischoff-Ferrari, MD, DrPH; Bess Dawson-Hughes, MD; E. John Orav, PhD; et al.
JAMA Intern Med. 2016;176(2):. doi:10.1001/jamainternmed.2015.7148.
Includes: Supplemental Content

Research Letter | 
Tanner J. Caverly, MD, MPH; Angela Fagerlin, PhD; Brian J Zikmund-Fisher, PhD; et al.
JAMA Intern Med. 2015;175(12):1994-1996. doi:10.1001/jamainternmed.2015.5950.

Original Investigation | 
Jeremy B. Sussman, MD, MS; Eve A. Kerr, MD, MPH; Sameer D. Saini, MD, MS; et al.
JAMA Intern Med. 2015;175(12):1942-1949. doi:10.1001/jamainternmed.2015.5110.
Includes: Supplemental Content

Original Investigation | 
Karen E. Hansen, MD, MS; R. Erin Johnson, BS; Kaitlin R. Chambers, BS; et al.
JAMA Intern Med. 2015;175(10):1612-1621. doi:10.1001/jamainternmed.2015.3874.
Includes: CME, Supplemental Content

Invited Commentary | 
Margaret E. Wierman, MD
JAMA Intern Med. 2015;175(7):1197-1198. doi:10.1001/jamainternmed.2015.1580.

Original Investigation | 
J. Bradley Layton, PhD; Christoph R. Meier, PhD, MSc; Julie L. Sharpless, MD; et al.
JAMA Intern Med. 2015;175(7):1187-1196. doi:10.1001/jamainternmed.2015.1573.
Includes: Supplemental Content

Invited Commentary | 
Hillary V. Kunins, MD, MPH, MS
JAMA Intern Med. 2015;175(6):987-988. doi:10.1001/jamainternmed.2015.0939.

Original Investigation |  FREE
Shelly L. Gray, PharmD, MS; Melissa L. Anderson, MS; Sascha Dublin, MD, PhD; et al.
JAMA Intern Med. 2015;175(3):401-407. doi:10.1001/jamainternmed.2014.7663.
Includes: Supplemental Content

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson, MD; Gary K. Schwartz, MD; Mary Louise Keohan, MD; et al.
JAMA Oncology
Brief Report  | 
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma
M. Estela Martinez-Escala, MD; Timothy M. Kuzel, MD; Jason B. Kaplan, MD; et al.
JAMA Oncology
Invited Commentary  | 
Romidepsin Therapy Over 5 Years in a Clinical Setting—Real-World Experience
Susan E. Bates, MD; Larisa J. Geskin, MD
JAMA Oncology
Research Letter  | 
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
Lecia V. Sequist, MD, MPH; Zofia Piotrowska, MD; Matthew J. Niederst, PhD; et al.